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Abstract (170 words) 
At the 2014 annual meeting of the Group for Research and Assessment of Psoriasis and 
Psoriatic Arthritis (GRAPPA), the psoriatic arthritis (PsA) working group of OMERACT (Outcome 
Measures in Rheumatology) presented a review of the progress made at the 2014 OMERACT 
meeting.  Members of the PsA OMERACT working group presented work from the Patient 
Involvement in Outcome Measures for PsA initiative to improve the incorporation of patient 
research partners in PsA outcomes research, the results of discussions within the OMERACT 
breakout groups, and finally the voting results.  The OMERACT 2014 participants had endorsed 
the need to update the PsA core set according to the Filter 2.0 framework.  The breakout group 
discussions identified potential opportunities for revising the core set, including consolidating 
existing redundancy within the core set, improving incorporation of the patient perspective, and 
including disease impacts such as fatigue as a core criterion.  GRAPPA members of the 
OMERACT working group now have a program of research to update the core set with the goal 
of seeking endorsement at OMERACT 2016.  
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Introduction 
 In 2006, at the eighth meeting of Outcome Measures in Rheumatology (OMERACT 8), 
members endorsed the psoriatic arthritis (PsA) core set of outcome measures to be used in 
randomized controlled trials (RCTs) and longitudinal observational studies.(1) Considerable 
work within the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) has been undertaken over the last eight years to develop appropriate individual and 
composite responder indices to capture disease activity.(2, 3)  At the OMERACT 10 meeting in 
2012, it became clear that much of the work of outcome measure development and domain 
selection had been undertaken with little or no incorporation of the patient perspective.  The role 
of patients in outcome research is embedded at the heart of the OMERACT process,(4, 5) and 
has been accomplished through meaningful, ongoing inclusion of patient research partners 
(PRPs)  In rheumatoid arthritis (RA), the acknowledged benefits of patient involvement have 
included the improved determination of the minimum clinically important differences (MCID) in 
patient-reported outcomes, development of definitions of remission and flare, and inclusion of 
fatigue and participation to the RA core set.(6, 7)   
 A number of initiatives on both sides of the Atlantic are underway to firmly embed the 
patient perspective in wider health research.  The United States Congress has established the 
Patient Centered Outcomes Research Institute, the National Institute of Health Research in the 
United Kingdom has convened the INVOLVE group to promote patient involvement in the 
National Health Service, and the European League Against Rheumatism has published 
recommendations for the inclusion of the patient perspective in research.(8)   
 At the 2014 GRAPPA annual meeting, the PsA OMERACT working group presented a 
summary of the work of the Patient Involvement in Outcome Measures for Psoriatic Arthritis 
(PIOMPSA) group over the last two years.  Results were also presented of the breakout group 
discussions and attendee voting at OMERACT 12, as well as a potential roadmap toward 
endorsement of a revised PsA core set at OMERACT 13 in 2016.   
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Presentations 
The OMERACT 12 Psoriatic Arthritis working group overview 
 Dr. Niti Goel introduced the PsA OMERACT working group comprising two fellows, four 
co-chairs, three PRPs, one member of the OMERACT executive committee for liaison, and two 
additional GRAPPA member attendees (see Acknowledgments).  The OMERACT PsA 
workshop consisted of presentations of the work undertaken since OMERACT 10 including the 
PIOMPSA initiative,(9) the Psoriatic Arthritis Impact of Disease (PsAID) study,(10) and the 
progress made towards development of composite disease activity measures.(2)  Presentations 
at OMERACT were followed by breakout group discussions on the need to update the PsA core 
set and what revisions should be considered.  Results from breakout groups were presented at 
a plenary session, followed by voting.(11)   
 
Review of the patient involvement initiative (PIOMPSA)  
 The PIOMPSA effort was initiated in 2012 to improve incorporation of the patient 
perspective in PsA outcomes research within GRAPPA.  The first meeting in Dublin, Ireland 
included equal numbers of rheumatologists and PRPs, and efforts have been made to preserve 
this balance to give PRPs an equal voice at the proceedings.(9)  The PIOMPSA group 
discussed the relative lack of patient input in the development of the PsA core set and outcome 
measure development.  They also undertook a systematic literature review to define current 
levels of patient involvement together with developing a roadmap to enhance integration of 
patient perspectives in future PsA research.  The group identified the need to revise the existing 
PsA core set, primarily to ensure incorporation of patient involvement in domain selection and 
prioritization, but additionally to integrate the considerable research progress from 2006 onward, 
including;  
 The 68/66 (tender/swollen) joint count has been identified as the optimal joint count for 
PsA assessment in clinical trials.(12)   
 Tools to assess fatigue, enthesitis, dactylitis, and the measurement of axial disease 
have been developed and tested.(13-15)  
 The Psoriasis Activity and Severity Index has been shown to be reliable when performed 
by rheumatologists or dermatologists.(16)   
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 Updating the core set in light of these research findings would facilitate patient 
representation.  It would also allow an opportunity for movement or incorporation of domains 
important to patients such as fatigue, dactylitis, and participation (work/leisure activities) that 
were not previously included.(9, 17)  Dr. Goel acknowledged that the PRP role within GRAPPA 
needed to be formalized through the work done in the Building Bridges initiative.(18)   
 
Update of the PsA core set, breakout group discussion and voting 
 Dr. William Tillett reviewed the results of the 2014 OMERACT 12 breakout discussions 
and voting.  The existing PsA core set, endorsed at OMERACT 8 in 2006, was reviewed 
(Figure 1)(1) and compared with the new OMERACT Filter 2.0.(19)  The new structure 
encourages researchers to consider domains within four core areas:  pathophysiological 
manifestations, life impact, resource use, and death (Figure 2).(19)  Domains are then placed 
within concentric spheres by decreasing importance and/or availability of applicable instruments 
and finally for the research agenda.  The core (central) sphere should contain at least one 
domain from each of the four core areas.  The middle sphere could contain several additional 
domains that may not be applicable for the central sphere but could be useful dependent on the 
individual study question.  The final outer sphere could be reserved for additional domains of 
interest in the research agenda.  Participants at the OMERACT workshop breakout groups were 
given a copy of the existing PsA core set and asked to consider the need for its revision and if 
so what changes to consider. 
 Feedback from the breakout groups identified a number of themes. There was general 
agreement on the need to revise the PsA core set, which would present opportunities to 
improve the existing set.  An opportunity to amend existing redundancy within the core area of 
pathophysiology was discussed.  An umbrella term such as inflammatory musculoskeletal 
disease for arthritis, enthesitis, dactylitis, and axial disease could be considered.  Psoriasis 
activity may be considered as an encompassing term for skin and nail disease, and biomarkers 
for acute phase reactants.  Life impact concepts emerging from the breakout discussions 
included a strong message to retain pain, health-related quality of life, physical function, and 
patient global in the core set, while adding fatigue, which attendees noted had also been ranked 
highly in the PsAID study.(10)  Debate followed regarding the potential overlap of domains 
captured in the patient global measure as well as fatigue, with recognition of the increasing 
evidence that it is legitimate to move items like dactylitis,(20) fatigue,(21) and enthesitis(22) 
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from former positions in the second circle to higher prioritization in the inner circle, especially as 
tools had been developed and tested since the initial core set was created.  
 The proposal to revise the PsA core set was endorsed with a 100% vote by the 
OMERACT workshop participants—notably the first time a unanimous vote had been achieved 
within OMERACT.  The PsA core set will therefore be the first to undergo revision using the 
OMERACT Filter 2.0.  Consensus was also achieved on retaining the patient global within the 
core set (endorsed with 70% vote) as well as adding fatigue (endorsed with 72% vote).   
 
Conclusion 
 At the 2014 OMERACT 12 PsA workshop there was unanimous endorsement for the 
need to update the PsA core set.  The results of the OMERACT breakout group discussions 
highlighted opportunities to involve patients as well as add, move, or merge existing domains to 
improve existing redundancy.  Over the next two years, GRAPPA working group members will 
focus on revising the PsA core set according to the OMERACT Filter 2.0, with the goal of 
seeking endorsement at OMERACT 13 in 2016.  
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 Figure 1:  Domains for PsA. (Reproduced with kind permission from The Journal of 
Rheumatology)(1) 
 
 
 
CT = Computed Tomography; MRI = Magnetic Resonance Imaging; PGA = Physician Global 
Assessment; US = Ultrasound  
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Figure 2:  Conceptual framework for core areas. (Reproduced with kind permission)(19) 
 
 
 
 
 
Concepts 
Core Areas 
Domains 
Impact of 
 Health Conditions 
Pathophysiological 
 Manifestations 
Pathophysiological 
 Manifestations Death 
Life 
Impact 
Resource Use / 
Economical Impact 
Examples of 
specific Domains 
within Areas  
 disease  ICF domains: activity  societal  ICF: body function  
 intervention  and participation  individual  and structure 
   quality of life  health care  organ function 
   patient perception of  direct/indirect  (eg lung function) 
   health  (productivity)  reversible 
   loss of ability to work  intangible  manifestations 
   psychosocial impact  costs  irreversible 
   2ary impact on family,    manifestations 
   caregivers    biomarkers 
   utility     surrogate outcomes 
 
 
 
Adverse Events  
are measured within the core areas, 
but are labelled separately to allow 
assessment of benefit and harm.  
 
Choices Influenced by Context 
 
